Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to demonstrate that new treatments are as effective as a reference
triple-agent regimen in driving plasma viral load below the detection limit early during
treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
and tenofovir.
Phase:
Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators:
Gilead Sciences Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba Merck Sharp & Dohme Corp.
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lopinavir Nevirapine Ritonavir Tenofovir Zidovudine